HEALTH CARE COST AVOIDANCE DUE TO INSULIN GLARGINE FOR TYPE 2 DIABETIC PATIENTS IN HONG KONG AS COMPARED TO NPH INSULIN

被引：0
|
作者：
Lee, K. K. [1 ]
Wu, D. B. C. [2 ]
机构：
[1] Monash Univ, Selangor, Malaysia
[2] Monash Univ, Kuala Lumpur, Malaysia
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.735
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A451 / A451
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS STUDY TO EVALUATE INSULIN GLARGINE COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES UNCONTROLLED WITH ORAL ANTI-DIABETIC AGENTS IN HONG KONG
    Luk, A.
    Lau, E.
    Kong, A.
    So, W. Y.
    Chan, J. C.
    VALUE IN HEALTH, 2017, 20 (09) : A480 - A480
  • [2] Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis
    E. Lau
    A. Salem
    J. C. N. Chan
    W. Y. So
    A. Kong
    M. Lamotte
    A. Luk
    Cost Effectiveness and Resource Allocation, 17
  • [3] Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis
    Lau, E.
    Salem, A.
    Chan, J. C. N.
    So, W. Y.
    Kong, A.
    Lamotte, M.
    Luk, A.
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2019, 17 (1)
  • [4] Pharmacoeconomic analysis of insulin glargine compared with NPH insulin in patients with type 2 diabetes in Spain
    Terres, CR
    Rodríguez, J
    Bolinder, B
    De Pablos, P
    DIABETES, 2004, 53 : A291 - A291
  • [5] Cost-utility analysis of insulin glargine compared with NPH insulin in patients with type 1 diabetes in Spain
    Terrés, CR
    Rodríguez, J
    Bolinder, B
    De Pablos, P
    DIABETES, 2004, 53 : A291 - A292
  • [6] Economic evaluation of the use of insulin glargine compared with NPH insulin in patients with Type 2 diabetes in Spain
    Rodríguez, J
    Terrés, CR
    Bolinder, B
    de Pablos, P
    DIABETOLOGIA, 2004, 47 : A344 - A344
  • [7] Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective
    Evans, M.
    Wolden, M.
    Gundgaard, J.
    Chubb, B.
    Christensen, T.
    DIABETES OBESITY & METABOLISM, 2014, 16 (04): : 366 - 375
  • [8] INSULIN GLARGINE COMPARED TO INSULIN NPH FOR THE MANAGEMENT OF HYPERGLYCEMIA IN CRITICALLY ILL PATIENTS
    Anderson, Rebecca
    Fox, Marlena
    Danesh, Valerie
    Gupta, Rakesh
    Jones, Timothy
    CRITICAL CARE MEDICINE, 2012, 40 (12) : U284 - U285
  • [9] Diabetic retinopathy in patients with type 1 diabetes treated with insulin glargine or NPH
    Peters, K
    Garg, SK
    JAckson, WE
    Mackenzie, T
    Queen, J
    Anil, S
    Chase, HP
    DIABETES, 2001, 50 : A443 - A443
  • [10] Economic analysis of insulin glargine compared with NPH insulin in the treatment of patients with Type 1 diabetes in Spain
    Terrés, CR
    Rodríguez, J
    Bolinder, B
    de Pablos, P
    DIABETOLOGIA, 2004, 47 : A345 - A345
12345